Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View

Dominik Jarczak; Stefan Kluge; Axel Nierhaus

doi:10.3390/ijms21155543

Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View

Standard

Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View. / Jarczak, Dominik ; Kluge, Stefan ; Nierhaus, Axel.

In: INT J MOL SCI, Vol. 21, No. 15, 03.08.2020.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Jarczak, D , Kluge, S & Nierhaus, A 2020, 'Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View', INT J MOL SCI, vol. 21, no. 15. https://doi.org/10.3390/ijms21155543

APA

Jarczak, D., Kluge, S., & Nierhaus, A. (2020). Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View. INT J MOL SCI, 21(15). https://doi.org/10.3390/ijms21155543

Vancouver

Jarczak D , Kluge S , Nierhaus A. Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View. INT J MOL SCI. 2020 Aug 3;21(15). https://doi.org/10.3390/ijms21155543

Bibtex

@article{7644c4d14f524e4a9ce2399949aa1767,

title = "Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View",

abstract = "Sepsis is a life-threatening organ dysfunction, defined by a dysregulated host immune response to infection. During sepsis, the finely tuned system of immunity, inflammation and anti-inflammation is disturbed in a variety of ways. Both pro-inflammatory and anti-inflammatory pathways are upregulated, activation of the coagulation cascade and complement and sepsis-induced lymphopenia occur. Due to the manifold interactions in this network, the use of IgM-enriched intravenous immunoglobulins seems to be a promising therapeutic approach. Unfortunately, there is still a lack of evidence-based data to answer the important questions of appropriate patient populations, optimal timing and dosage of intravenous immunoglobulins. With this review, we aim to provide an overview of the role of immunoglobulins, with emphasis on IgM-enriched formulations, in the therapy of adult patients with sepsis and septic shock.",

author = "Dominik Jarczak and Stefan Kluge and Axel Nierhaus",

year = "2020",

month = aug,

day = "3",

doi = "10.3390/ijms21155543",

language = "English",

volume = "21",

journal = "INT J MOL SCI",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "15",

}

RIS

TY - JOUR

T1 - Use of Intravenous Immunoglobulins in Sepsis Therapy - A Clinical View

AU - Jarczak, Dominik

AU - Kluge, Stefan

AU - Nierhaus, Axel

PY - 2020/8/3

Y1 - 2020/8/3

N2 - Sepsis is a life-threatening organ dysfunction, defined by a dysregulated host immune response to infection. During sepsis, the finely tuned system of immunity, inflammation and anti-inflammation is disturbed in a variety of ways. Both pro-inflammatory and anti-inflammatory pathways are upregulated, activation of the coagulation cascade and complement and sepsis-induced lymphopenia occur. Due to the manifold interactions in this network, the use of IgM-enriched intravenous immunoglobulins seems to be a promising therapeutic approach. Unfortunately, there is still a lack of evidence-based data to answer the important questions of appropriate patient populations, optimal timing and dosage of intravenous immunoglobulins. With this review, we aim to provide an overview of the role of immunoglobulins, with emphasis on IgM-enriched formulations, in the therapy of adult patients with sepsis and septic shock.

AB - Sepsis is a life-threatening organ dysfunction, defined by a dysregulated host immune response to infection. During sepsis, the finely tuned system of immunity, inflammation and anti-inflammation is disturbed in a variety of ways. Both pro-inflammatory and anti-inflammatory pathways are upregulated, activation of the coagulation cascade and complement and sepsis-induced lymphopenia occur. Due to the manifold interactions in this network, the use of IgM-enriched intravenous immunoglobulins seems to be a promising therapeutic approach. Unfortunately, there is still a lack of evidence-based data to answer the important questions of appropriate patient populations, optimal timing and dosage of intravenous immunoglobulins. With this review, we aim to provide an overview of the role of immunoglobulins, with emphasis on IgM-enriched formulations, in the therapy of adult patients with sepsis and septic shock.

U2 - 10.3390/ijms21155543

DO - 10.3390/ijms21155543

M3 - SCORING: Review article

C2 - 32756325

VL - 21

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 15

ER -